Alessandra Bini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Alessandra Bini has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
B Kudryk
The New York Blood Center, New York, NY, USA
3 shared publicationsK L Kaplan
Columbia University, New York, NY, USA
3 shared publicationsBohdan J. Kudryk
From the Laboratory of Blood Coagulation Biochemistry (A.B., B.J.K.), Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY; the Department of Biochemistry (K.G.M.), University of Vermont, Burlington; and the Department of Pathology (F.J.S.), Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass
2 shared publicationsC Pirani
Departments of Medicine and Pathology, Columbia University, New York, NY, USA
1 shared publicationFrederick J. Schoen
From the Laboratory of Blood Coagulation Biochemistry (A.B., B.J.K.), Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY; the Department of Biochemistry (K.G.M.), University of Vermont, Burlington; and the Department of Pathology (F.J.S.), Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass
1 shared publicationHideaki Nagase
Laboratory of Blood Coagulation Biochemistry, The Lindsley F. Kimball Research Institute, The New York Blood Center, New York, New York 10021, and Department of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, Kansas 66160-7421
1 shared publication
Latest Publications
- 1 August 1999
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 19 (8) , 1852-1861
Noncollagenous Bone Matrix Proteins, Calcification, and Thrombosis in Carotid Artery Atherosclerosis
—Advanced atherosclerosis is often associated with dystrophic calcification, which may contribute to plaque rupture and thrombosis. In this work, the localization and association of the noncollagenous bone matrix proteins osteonectin, osteopontin, and osteocalcin with calcification, lipoproteins, thrombus/hemorrhage (T/H), and matrix metalloproteinases (MMPs) in human carotid arteries from endarterectomy samples have been determined. According to the recent American Heart Association classification, 6 of the advanced lesions studied were type V (fibroatheroma) and 16 type VI (complicated). Osteonectin, osteocalcin, and osteopontin were identified by monoclonal antibodies IIIA3A8, G12, and MPIIIB101and antiserum LF-123. Apolipoprotein (apo) AI, B, and E; lipoprotein(a); fibrinogen; fibrin; fragment D/D-dimer; MMP-2 (gelatinase A); and MMP-3 (stromelysin-1) were identified with previously characterized antibodies. Calcium phosphate deposits (von Kossa’s stain) were present in 82% of samples (3 type V and 15 type VI). Osteonectin was localized in endothelial cells, SMCs, and macrophages and was associated with calcium deposits in 33% of type V and 88% of type VI lesions. Osteopontin was distributed similarly to osteonectin and was associated with calcium deposits in 50% of type V and 94% of type VI lesions. Osteocalcin was localized in large calcified areas only (in 17% of type V and 38% of type VI lesions). ApoB colocalized with cholesterol crystals and calcium deposits. Lipoprotein(a) was localized in the intima, subintima, and plaque shoulder. Fibrin (T/H) colocalized with bone matrix proteins in 33% of type V and 69% of type VI lesions. MMP-3 was cytoplasmic in most cells and colocalized with calcium and fibrin deposits. MMP-2 was less often associated with calcification. The results of this study show that osteonectin, osteopontin, and osteocalcin colocalized with calcium deposits with apoB, fibrin, and MMP-3 in advanced, symptomatic carotid lesions. These data suggest that the occurrence of T/H might contribute to dystrophic arterial calcification in the progression and complications of atherosclerosis.
- 1 August 1999
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 19 (8) , 1852-1861
Noncollagenous Bone Matrix Proteins, Calcification, and Thrombosis in Carotid Artery Atherosclerosis
—Advanced atherosclerosis is often associated with dystrophic calcification, which may contribute to plaque rupture and thrombosis. In this work, the localization and association of the noncollagenous bone matrix proteins osteonectin, osteopontin, and osteocalcin with calcification, lipoproteins, thrombus/hemorrhage (T/H), and matrix metalloproteinases (MMPs) in human carotid arteries from endarterectomy samples have been determined. According to the recent American Heart Association classification, 6 of the advanced lesions studied were type V (fibroatheroma) and 16 type VI (complicated). Osteonectin, osteocalcin, and osteopontin were identified by monoclonal antibodies IIIA3A8, G12, and MPIIIB101and antiserum LF-123. Apolipoprotein (apo) AI, B, and E; lipoprotein(a); fibrinogen; fibrin; fragment D/D-dimer; MMP-2 (gelatinase A); and MMP-3 (stromelysin-1) were identified with previously characterized antibodies. Calcium phosphate deposits (von Kossa’s stain) were present in 82% of samples (3 type V and 15 type VI). Osteonectin was localized in endothelial cells, SMCs, and macrophages and was associated with calcium deposits in 33% of type V and 88% of type VI lesions. Osteopontin was distributed similarly to osteonectin and was associated with calcium deposits in 50% of type V and 94% of type VI lesions. Osteocalcin was localized in large calcified areas only (in 17% of type V and 38% of type VI lesions). ApoB colocalized with cholesterol crystals and calcium deposits. Lipoprotein(a) was localized in the intima, subintima, and plaque shoulder. Fibrin (T/H) colocalized with bone matrix proteins in 33% of type V and 69% of type VI lesions. MMP-3 was cytoplasmic in most cells and colocalized with calcium and fibrin deposits. MMP-2 was less often associated with calcification. The results of this study show that osteonectin, osteopontin, and osteocalcin colocalized with calcium deposits with apoB, fibrin, and MMP-3 in advanced, symptomatic carotid lesions. These data suggest that the occurrence of T/H might contribute to dystrophic arterial calcification in the progression and complications of atherosclerosis.
- 1 January 1996
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 35 (40) , 13056-13063
Degradation of Cross-Linked Fibrin by Matrix Metalloproteinase 3 (Stromelysin 1): Hydrolysis of the γ Gly 404−Ala 405 Peptide Bond
Matrix metalloproteinases (MMPs) can degrade a number of proteins that constitute the extracellular matrix. Previous studies have shown that atherosclerotic plaques contain substantial amounts of fibrin(ogen)-related antigen, and more recently, MMPs have been identified in such lesions. The hypothesis that MMPs play a role in the degradation of fibrinogen (Fg) and cross-linked fibrin (XL-Fb) was investigated. Fibrinogen became thrombin-unclottable when treated with matrix metalloproteinase 3 (MMP-3, stromelysin 1) but not with matrix metalloproteinase 2 (MMP-2, gelatinase A). Incubation of XL-Fb clots (made with 125I-Fg) with MMP-3 resulted in complete lysis after 24 h. A D monomer-like fragment was generated by MMP-3 degradation of fibrinogen, XL-Fb, and fragment DD. Immunoreactivity with monoclonal antibody (MoAb)/4-2 (anti-γ392−406) but not with MoAb/4A5 (anti-γ397−411) suggested that a major cleavage site was within the sequence participating in the cross-linking of two γ-chains. NH2-terminal sequence analysis of the γ-chain of the D monomer-like fragment and of a dipeptide isolated from the MMP-3 digest of XL-fibrin identified the hydrolysis of the γ Gly 404-Ala 405 peptide bond. These data indicate that the degradation of Fg and XL-Fb by MMP-3 is specific and different from plasmin. This mechanism of fibrinolysis might be of relevance in wound healing, inflammation, atherosclerosis, and other pathophysiological processes.
- 1 January 1996
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 35 (40) , 13056-13063
Degradation of Cross-Linked Fibrin by Matrix Metalloproteinase 3 (Stromelysin 1): Hydrolysis of the γ Gly 404−Ala 405 Peptide Bond
Matrix metalloproteinases (MMPs) can degrade a number of proteins that constitute the extracellular matrix. Previous studies have shown that atherosclerotic plaques contain substantial amounts of fibrin(ogen)-related antigen, and more recently, MMPs have been identified in such lesions. The hypothesis that MMPs play a role in the degradation of fibrinogen (Fg) and cross-linked fibrin (XL-Fb) was investigated. Fibrinogen became thrombin-unclottable when treated with matrix metalloproteinase 3 (MMP-3, stromelysin 1) but not with matrix metalloproteinase 2 (MMP-2, gelatinase A). Incubation of XL-Fb clots (made with 125I-Fg) with MMP-3 resulted in complete lysis after 24 h. A D monomer-like fragment was generated by MMP-3 degradation of fibrinogen, XL-Fb, and fragment DD. Immunoreactivity with monoclonal antibody (MoAb)/4-2 (anti-γ392−406) but not with MoAb/4A5 (anti-γ397−411) suggested that a major cleavage site was within the sequence participating in the cross-linking of two γ-chains. NH2-terminal sequence analysis of the γ-chain of the D monomer-like fragment and of a dipeptide isolated from the MMP-3 digest of XL-fibrin identified the hydrolysis of the γ Gly 404-Ala 405 peptide bond. These data indicate that the degradation of Fg and XL-Fb by MMP-3 is specific and different from plasmin. This mechanism of fibrinolysis might be of relevance in wound healing, inflammation, atherosclerosis, and other pathophysiological processes.
- 1 July 1987
- Published by Georg Thieme Verlag KG
- Vol. 58 (01) , 0282
DISTRIBUTION AND IDENTIFICATION OF FIBRINOGEN, FIBRIN AND DEGRADATION PRODUCTS IN ATHEROSCLEROSIS BY MONOCLONAL ANTIBODIES
Specimens from vascular surgery and from heart transplant recipients were examined. The tissues were stained with the avidin biotin complex-immunoperoxidase technique using specific monoclonal antibodies (MAbs) for fibrinogen and fibrin. MAb I8C6 detects fibrinogen and fibrin I, MAb T2G1 is specific for fibrin II, MAb GC4 recognizes fragments D and D-D and does not cross-react with fibrinogen. Polyclonal antisera for fibrinogen, albumin and IgG were used as controls or as markers of increased vessel wall permeability. Serial sections of each specimen were stained with all the antibodies and the distribution of the different antigens compared. In samples of 4 normal thoracic aortas fibrinogen was present in 3/14 sections from different areas. Fibrin II and degradation products were absent. In 7 fibrous plaques, fibrinogen, fibrin II and fragment D were present, distributed in strands or in focal deposits. In most cases a stellate, patchy pattern of distribution was observed for fibrinogen and fibrin II suggestive of association with vessel wall cells and macrophages. In 7 complicated plaques fibrin II was always associated with fibrinogen, fragment D, albumin and IgG in areas of thrombus and these antigens were also present around cholesterol crystals and calcium deposits. In less severely affected areas some fibrinogen was focally distributed and fragment D was associated with fibrin II in granulation tissue. In three coronaries, fibrinogen and fibrin II were distributed in areas of early or fibrous plaque in which no fragment D was detected. In all the samples albumin and IgG were associated with fibrinogen and fibrin deposits suggesting penetration of plasma proteins into the vessel wall. These results indicate that polymerization and degradation of fibrin might occur not only on the luminal surface, but also within the vessel wall with cellular participation, thus contributing to the evolution of the atherosclerotic lesion. The use of specific monoclonal antibodies has made it possible to distinguish the distribution of fibrinogen and fibrin I, fibrin II and fragments D and D-D in normal and atherosclerotic vessels.
- 1 July 1987
- Published by Georg Thieme Verlag KG
- Vol. 58 (01) , 0282
DISTRIBUTION AND IDENTIFICATION OF FIBRINOGEN, FIBRIN AND DEGRADATION PRODUCTS IN ATHEROSCLEROSIS BY MONOCLONAL ANTIBODIES
Specimens from vascular surgery and from heart transplant recipients were examined. The tissues were stained with the avidin biotin complex-immunoperoxidase technique using specific monoclonal antibodies (MAbs) for fibrinogen and fibrin. MAb I8C6 detects fibrinogen and fibrin I, MAb T2G1 is specific for fibrin II, MAb GC4 recognizes fragments D and D-D and does not cross-react with fibrinogen. Polyclonal antisera for fibrinogen, albumin and IgG were used as controls or as markers of increased vessel wall permeability. Serial sections of each specimen were stained with all the antibodies and the distribution of the different antigens compared. In samples of 4 normal thoracic aortas fibrinogen was present in 3/14 sections from different areas. Fibrin II and degradation products were absent. In 7 fibrous plaques, fibrinogen, fibrin II and fragment D were present, distributed in strands or in focal deposits. In most cases a stellate, patchy pattern of distribution was observed for fibrinogen and fibrin II suggestive of association with vessel wall cells and macrophages. In 7 complicated plaques fibrin II was always associated with fibrinogen, fragment D, albumin and IgG in areas of thrombus and these antigens were also present around cholesterol crystals and calcium deposits. In less severely affected areas some fibrinogen was focally distributed and fragment D was associated with fibrin II in granulation tissue. In three coronaries, fibrinogen and fibrin II were distributed in areas of early or fibrous plaque in which no fragment D was detected. In all the samples albumin and IgG were associated with fibrinogen and fibrin deposits suggesting penetration of plasma proteins into the vessel wall. These results indicate that polymerization and degradation of fibrin might occur not only on the luminal surface, but also within the vessel wall with cellular participation, thus contributing to the evolution of the atherosclerotic lesion. The use of specific monoclonal antibodies has made it possible to distinguish the distribution of fibrinogen and fibrin I, fibrin II and fragments D and D-D in normal and atherosclerotic vessels.
- 1 July 1987
- Published by Georg Thieme Verlag KG
- Vol. 58 (01) , 0517
SPECIFIC DETECTION OF FIBRIN IN HUMAN TISSUES BY A NEW IMMUNOHISTOCHEMICAL TECHNIQUE.
Human biopsy (30), surgical (50) and autopsy (14) specimens of different embryonic origin (skin, blood vessel, kidney, lymph nodes, prostate, lung, liver, and intestine) were stained by the avidin-biotin complex immunoperoxidase technique (ABC-IP) with monoclonal antibodies (MAbs). MAb T2G1 (recognizes 315-42 and detects fibrin II in tissues), MAb I8C6 (recognizes BS1-42 and indicates fibrinogen and fibrin I), MAb GC4 (specific for fragments D and D-D), and a polyclonal antiserum for fibrinogen. The method can be applied to frozen or Boilin’s fixed paraffin embedded tissues with good preservation of morphology and high sensitivity at the light microscopy level. The results were compared with conventional histochemical stains currently used in surgical pathology to demonstrate fibrin deposits in tissues. These stains are based on the acidophilic properties of fibrin (Fraser-Lendrum for “more recent” and Mallory’s PTAH for “older” fibrin). ABC-IP staining with MAb T2G1 clearly detected fibrin in areas where Lendrum and PTAH failed to reveal fibrin deposits, e.g., in the intercellular and pericellular matrix, as well as in areas where staining occurred with conventional techniques, indicating greater sensitivity of the ABC-IP method. Fibrin was specifically detected in strands or clumps in some areas of inflammation and granulation tissue and seemed to be associated with platelets and macrophages. Moreover, ABC-IP with MAb I8C6 and MAb GC4 permits the distinction between fibrinogen or fibrin I, and D and D dimer which are poorly reactive with the Lendrum and PTAH methods. The polyclonal antiserum for fibrinogen showed reactivity with all the material stained with the MAbs and with some additional areas due to the epitopes of fibrinogen and fibrin not detected by the monoclonals. The ABC-IP technique with MAbs allows specific demonstration of fibrin deposits in tissues. Moreover, these results indicate that this method facilitates the correlation of the morphologic appearance of fibrinogen) -related deposits in tissues with their molecular form and will be useful to elucidate the role of fibrin in diseases such as atherosclerosis, kidney disease, and tumors.
- 1 July 1987
- Published by Georg Thieme Verlag KG
- Vol. 58 (01) , 0517
SPECIFIC DETECTION OF FIBRIN IN HUMAN TISSUES BY A NEW IMMUNOHISTOCHEMICAL TECHNIQUE.
Human biopsy (30), surgical (50) and autopsy (14) specimens of different embryonic origin (skin, blood vessel, kidney, lymph nodes, prostate, lung, liver, and intestine) were stained by the avidin-biotin complex immunoperoxidase technique (ABC-IP) with monoclonal antibodies (MAbs). MAb T2G1 (recognizes 315-42 and detects fibrin II in tissues), MAb I8C6 (recognizes BS1-42 and indicates fibrinogen and fibrin I), MAb GC4 (specific for fragments D and D-D), and a polyclonal antiserum for fibrinogen. The method can be applied to frozen or Boilin’s fixed paraffin embedded tissues with good preservation of morphology and high sensitivity at the light microscopy level. The results were compared with conventional histochemical stains currently used in surgical pathology to demonstrate fibrin deposits in tissues. These stains are based on the acidophilic properties of fibrin (Fraser-Lendrum for “more recent” and Mallory’s PTAH for “older” fibrin). ABC-IP staining with MAb T2G1 clearly detected fibrin in areas where Lendrum and PTAH failed to reveal fibrin deposits, e.g., in the intercellular and pericellular matrix, as well as in areas where staining occurred with conventional techniques, indicating greater sensitivity of the ABC-IP method. Fibrin was specifically detected in strands or clumps in some areas of inflammation and granulation tissue and seemed to be associated with platelets and macrophages. Moreover, ABC-IP with MAb I8C6 and MAb GC4 permits the distinction between fibrinogen or fibrin I, and D and D dimer which are poorly reactive with the Lendrum and PTAH methods. The polyclonal antiserum for fibrinogen showed reactivity with all the material stained with the MAbs and with some additional areas due to the epitopes of fibrinogen and fibrin not detected by the monoclonals. The ABC-IP technique with MAbs allows specific demonstration of fibrin deposits in tissues. Moreover, these results indicate that this method facilitates the correlation of the morphologic appearance of fibrinogen) -related deposits in tissues with their molecular form and will be useful to elucidate the role of fibrin in diseases such as atherosclerosis, kidney disease, and tumors.
- 1 July 1987
- Published by Georg Thieme Verlag KG
- Vol. 58 (01) , 0520
MONOCLONAL ANTIBODY IDENTIFICATION OF FIBRIN DEPOSITS IN RENAL DISEASE
Glomerular and vascular "fibrin" deposition has frequently been reported in human and experimental renal diseases. The biochemical form of this "fibrin" has not been well defined. We studied 16 renal biopsies (Bouin's fixed paraffin embedded) with the ABC-immunoperoxidase technique using monoclonal antibodies (MAbs); MAb I8C6 (Bβ1-42) to fibrinogen and fibrin I; MAb T2G1 (β15-42) to fibrin II; and MAb GC4 to fragment D or D-D. Polyclonal antisera to fibrinogen, albumin and IgG were used as controls. Renal biopsy specimens included 9 cases of microangiopathy (Group I: 6 hemolytic uremic syndrome (HUS), 1 sclerodero-ma, 2 acute humoral rejection) and 7 miscellaneous cases of other renal disease (Group II: 2 IgA nephropathy, 2 minimal change disease, 2 membranous GN, 1 acute interstitial nephritis). Fibrinogen and fibrin I were present on the glomerular (glom) endothelial cells in 8/9 Group I and 7/7 Group II cases, but was present in glom capillary lumens in Group I only. Staining of the endothelial aspect of interstitial capillaries, arterioles and arteries was also observed in both groups. Fibrin II was present in most glom and interstitial capillaries in both groups. However, intense staining for fibrin II was observed in arterioles and arteries in Group I only. Staining for fragments D and D-D was observed in glom capillaries in 6 Group I cases (6 HUS) and 3 Group II cases (2 IgA nephropathy, 1 membranous GN) but was most diffuse and intense in Group I. Traditional histochemical stains for fibrin (Lendrum and PTAH) were positive in 4 Group I cases only, indicating that the ABC technique is far more sensitive. Controls (14 needle biopsies of non-renal tissue) showed no vascular ractivity for fibrinogen, fibrin I, II and fragments D and D-D, suggesting that the vascular staining observed in renal biopsy tissue is not caused by the biopsy procedure itself. These findings indicate that 1) Fibrin formation and lysis occur in many renal diseases of both vascular and non—vascular origin. 2) Fibrinolytic activity is higher in the glom capillaries than in the larger vessels. 3) Damaged renal endothelium may be an active participant in these processes.
- 1 July 1987
- Published by Georg Thieme Verlag KG
- Vol. 58 (01) , 0520
MONOCLONAL ANTIBODY IDENTIFICATION OF FIBRIN DEPOSITS IN RENAL DISEASE
Glomerular and vascular "fibrin" deposition has frequently been reported in human and experimental renal diseases. The biochemical form of this "fibrin" has not been well defined. We studied 16 renal biopsies (Bouin's fixed paraffin embedded) with the ABC-immunoperoxidase technique using monoclonal antibodies (MAbs); MAb I8C6 (Bβ1-42) to fibrinogen and fibrin I; MAb T2G1 (β15-42) to fibrin II; and MAb GC4 to fragment D or D-D. Polyclonal antisera to fibrinogen, albumin and IgG were used as controls. Renal biopsy specimens included 9 cases of microangiopathy (Group I: 6 hemolytic uremic syndrome (HUS), 1 sclerodero-ma, 2 acute humoral rejection) and 7 miscellaneous cases of other renal disease (Group II: 2 IgA nephropathy, 2 minimal change disease, 2 membranous GN, 1 acute interstitial nephritis). Fibrinogen and fibrin I were present on the glomerular (glom) endothelial cells in 8/9 Group I and 7/7 Group II cases, but was present in glom capillary lumens in Group I only. Staining of the endothelial aspect of interstitial capillaries, arterioles and arteries was also observed in both groups. Fibrin II was present in most glom and interstitial capillaries in both groups. However, intense staining for fibrin II was observed in arterioles and arteries in Group I only. Staining for fragments D and D-D was observed in glom capillaries in 6 Group I cases (6 HUS) and 3 Group II cases (2 IgA nephropathy, 1 membranous GN) but was most diffuse and intense in Group I. Traditional histochemical stains for fibrin (Lendrum and PTAH) were positive in 4 Group I cases only, indicating that the ABC technique is far more sensitive. Controls (14 needle biopsies of non-renal tissue) showed no vascular ractivity for fibrinogen, fibrin I, II and fragments D and D-D, suggesting that the vascular staining observed in renal biopsy tissue is not caused by the biopsy procedure itself. These findings indicate that 1) Fibrin formation and lysis occur in many renal diseases of both vascular and non—vascular origin. 2) Fibrinolytic activity is higher in the glom capillaries than in the larger vessels. 3) Damaged renal endothelium may be an active participant in these processes.